🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

RecruitingPhase 1Ages 18 Years - anyAllDeciphera Pharmaceuticals, LLC
NCT06966024 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Key Inclusion Criteria: * Have confirmed Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer * Able to take oral medication * If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements * Adequate organ function and electrolytes Key Exclusion Criteria: * Received any prior anticancer therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-2812 * Impaired cardiac function * Major surgery within 28 days of the first dose of study drug
💊

What it tests

  • DCC-2812
📍

Where

8 sites
Dana-Farber Cancer Institute
Boston, United States
University of Michigan
Ann Arbor, United States
Washington University School of Medicine
St Louis, United States
Cleveland Clinic
Cleveland, United States
Fox Chase Cancer Center
Philadelphia, United States
Vanderbilt- Ingram Cancer Center
Nashville, United States
NEXT Oncology, Austin
Austin, United States
NEXT Oncology, San Antonio
San Antonio, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy